Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Pharma’s Renaissance

We are on the verge of a medical renaissance, a period of accelerated progress in the treatment and management of rare diseases. This reawakening also brings with it challenges that we must grapple with.

Read More »

Novartis’ SMA Gene Therapy Treatment Approved by FDA, Priced at $2.125 Million

The U.S. Food and Drug Administration approved Zolgensma, a gene therapy that Novartis called a life-changing medicine, for children younger than 2 years of age who have been diagnosed with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 gene.

Read More »

Future of Agencies

There has been a void in the healthcare industry and there is a need for agencies to become more efficient and cost-effective to reflect these new challenges.

Read More »

Catalent entering gene therapy market via Paragon buy

Catalent Inc. will buy privately held Paragon Bioservices Inc. for $1.2 billion in cash, bolstering the contract drugmaker’s capabilities to make gene therapy drugs for biotech clients.

Read More »

Coeptis Pharma Buys Elto Pharma for Phase II Parkinson’s Asset

Wexford, Pa.-based Coeptis Pharmaceuticals is buying New York-based Elto Pharma, which is a joint venture between Amarantus Bioscience Holdings and PsychoGenics.

Read More »

GSK seeks mid-September 2018 bids for $4 billion Indian Horlicks unit: sources

GlaxoSmithKline is seeking initial bids by mid-September for the company’s India-focused Horlicks health nutrition business, which is expected to fetch more than $4 billion, two people familiar with the situation said.

Read More »

Shire’s Sales Up Ahead of Takeda Acquisition

As Shire’s acquisition by Takeda Pharmaceutical approaches, the global biotechnology company reported a solid second-quarter 2018.

Read More »

Dermavant Bags GSK Phase III-Ready Psoriasis Treatment in $330 Million Deal

Months after tapping GlaxoSmithKline dermatology division executive David Rubenstein as its new chief scientific officer, Vivek Ramaswamy’s Dermavant Sciences returned to the pharma giant to acquire a Phase III-ready psoriasis treatment.

Read More »

Abingworth Closes on $315 Million Fund Aimed at Life Science Companies in Europe and the U.S.

Abingworth Bioventures closed out its latest investment fund aimed at supporting life science companies with $315 million. The latest fund, ABV VII, will be used to support investments in Europe and the United States.

Read More »

A Behind-the-Scenes Look at Takeda Pharma’s Takeover of Shire

  By Mark Terry   The ink is still drying on the contracts for Japan’s Takeda Pharmaceutical’s acquisition of Dublin-based Shire for about $62.2 billion, but company executives are sharing some of the “inside baseball” about what went on behind the scenes of the deal. Takeda originally planned to approach Shire’s board of directors about the acquisition on April 1, but published rumors […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!


Ad Right Bottom